Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing chemotherapy and targeted agent combinations in NSCLC.

Thomas Lynch1, Edward Kim

  • 1Massachusetts General Hospital, Boston, MA, USA.

Lung Cancer (Amsterdam, Netherlands)
|March 23, 2006
PubMed
Summary

Chemotherapy offers survival benefits for advanced non-small cell lung cancer (NSCLC). Adding bevacizumab to chemotherapy improved survival in specific NSCLC patients, while targeted therapies show promise in combination regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fast large scale full-wave multiple-scattering computation for three-dimensional random rough surfaces.

Scientific reports·2026
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

Age-related differences in psychological distress and persistent postsurgical pain after surgery for management of non-invasive breast lesions.

Breast cancer research and treatment·2026
Same author

How I Do It: "And That's a BINGO!" Using a Self-Directed, Gamified Instrument to Structure Learning on the Obstetrics Clerkship.

Journal of surgical education·2026
Same author

[<sup>68</sup>Ga]Ga-DOTA-5G PET/CT Detects Brain and Bone Metastases in a Patient with Metastatic Pancreatic Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma.

Radiology·2026

Area of Science:

  • Medical Oncology
  • Clinical Trials
  • Pharmacology

Background:

  • Chemotherapy is a standard treatment for advanced non-small cell lung cancer (NSCLC), offering survival extension and symptom palliation.
  • Despite numerous trials, traditional cytotoxic chemotherapy regimens have reached a plateau in improving survival rates.
  • The addition of novel targeted agents to chemotherapy has largely failed to demonstrate significant survival benefits in advanced NSCLC.

Purpose of the Study:

  • To evaluate the efficacy of novel therapeutic strategies in advanced non-small cell lung cancer.
  • To identify patient subgroups that may benefit from specific targeted therapies.
  • To explore synergistic combinations of chemotherapy and targeted agents for improved treatment outcomes.

Main Methods:

Related Experiment Videos

  • Review of numerous clinical trials evaluating doublet chemotherapy regimens and targeted agents in advanced NSCLC.
  • Analysis of the E4599 trial results regarding the addition of bevacizumab to paclitaxel-carboplatin chemotherapy.
  • Examination of preclinical modeling for synergistic drug combinations and ongoing clinical trials.

    • Main Results:

    • Erlotinib or gefitinib added to chemotherapy did not improve survival, but erlotinib monotherapy showed benefit in second- and third-line settings.
    • The E4599 trial demonstrated that bevacizumab addition to paclitaxel-carboplatin chemotherapy extended survival in patients with non-squamous cell NSCLC.
    • Identifying subgroups for potential benefit or increased toxicity (e.g., squamous cell carcinoma with bevacizumab) is crucial.

    Conclusions:

    • Bevacizumab combined with paclitaxel-carboplatin chemotherapy shows efficacy in a select group of non-squamous NSCLC patients.
    • Large, well-designed randomized trials are valuable for identifying optimal targeted therapy combinations and patient subgroups.
    • Ongoing trials are investigating combinations of chemotherapy with EGFR inhibitors, VEGF inhibitors, proteasome inhibitors, COX2 inhibitors, and immunomodulators.